Verona Pharma PLC
NASDAQ:VRNA
Verona Pharma PLC
Net Income (Common)
Verona Pharma PLC
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Verona Pharma PLC
NASDAQ:VRNA
|
Net Income (Common)
-$54.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Net Income (Common)
£4.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
AstraZeneca PLC
LSE:AZN
|
Net Income (Common)
$6.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
|
Indivior PLC
LSE:INDV
|
Net Income (Common)
$5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Net Income (Common)
$190m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Net Income (Common)
-£27.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Verona Pharma PLC's Net Income (Common)?
Net Income (Common)
-54.4m
USD
Based on the financial report for Dec 31, 2023, Verona Pharma PLC's Net Income (Common) amounts to -54.4m USD.
What is Verona Pharma PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-15%
Over the last year, the Net Income (Common) growth was 21%. The average annual Net Income (Common) growth rates for Verona Pharma PLC have been 6% over the past three years , -15% over the past five years .